Browsing CRIStin høstingsarkiv by Author "Waage, Anders"

Now showing items 1-8 of 8

  • BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis 
    Rustad, Even Holth; Dai, Hong Yan; Hov, Håkon; Coward, Eivind; Beisvag, Vidar; Myklebost, Ola; Hovig, Eivind; Nakken, Sigve; Vodak, Daniel; Meza-Zepeda, Leonardo A.; Sandvik, Arne Kristian; Wader, Karin Fahl; Misund, Kristine; Sundan, Anders; Aarset, Harald; Waage, Anders (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies were screened for BRAF ...
  • Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group 
    Gregersen, Henrik; Peceliunas, Valdas; Remes, Kari; Schjesvold, Fredrik Hellem; Abildgaard, Niels; Nahi, Hareth; Andersen, Niels Frost; Vangsted, Annette Juul; Klausen, Tobias Wirenfeldt; Helleberg, Carsten; Carlson, Kristina; Frølund, Ulf Christian; Axelsson, Per; Stromberg, Olga; Blimark, Cecilie Hveding; Crafoord, Jacob; Tsykunova, Galina; Eshoj, Henrik Rode; Waage, Anders; Hansson, Markus; Gulbrandsen, Nina (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    Objective We investigated the efficacy and safety of carfilzomib-containing induction before salvage high-dose melphalan with autologous stem-cell transplantation (salvage ASCT) and maintenance with carfilzomib and ...
  • Chemical, Physical and Biological Triggers of Evolutionary Sonserved Bcl-xL-Mediated Apoptosis 
    Ianevski, Aleksandr; Kulesskiy, Evgeny; Krpina, Klara; Lou, Guofeng; Aman, Yahyah; Bugai, Andrii; Aasumets, Koit; Akimov, Yevhen; Bulanova, Daria; Gildemann, Kiira; Arutyunyan, Albert F.; Susova, Olga Yu.; Zhuze, Alexei L.; Ji, Ping; Wang, Wei; Holien, Toril; Bugge, Marit; Zusinaite, Eva; Oksenych, Valentyn; Lysvand, Hilde; Gerhold, Joachim M.; Bjørås, Magnar; Johansen, Pål; Waage, Anders; Heckman, Caroline A.; Fang, Evandro Fei; Kainov, Denis (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)
    Background: The evidence that pan-Bcl-2 or Bcl-xL-specific inhibitors prematurely kill virus-infected or RNA/DNA-transfected cells provides rationale for investigating these apoptotic inducers further. We hypothesized that ...
  • Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence 
    Misund, Kristine; Hofste op Bruinink, Davine; Coward, Eivind; Hoogenboezem, Remco M.; Rustad, Even Holth; Sanders, Mathijs A.; Rye, Morten Beck; Sponaas, Anne-Marit; van der Holt, Bronno; Zweegman, Sonja; Hovig, Eivind; Meza, Leonardo Zepeda; Sundan, Anders; Myklebost, Ola; Sonneveld, Pieter; Waage, Anders (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Abstract We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study before and after treatment. A change in clonal ...
  • Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells 
    Aass, Kristin Roseth; Mjelle, Robin; Kastnes, Martin Haugrud; Tryggestad, Synne Stokke; van den Brink, Luca M; Roseth, Ingrid Aass; Westhrin, Marita; Zahoor, Muhammad; Moen, Siv Helen; Nedal, Tonje Marie Vikene; Buene, Glenn; Misund, Kristine; Sponaas, Anne-Marit; Ma, Qianli; Sundan, Anders; Groen, Richard WJ; Slørdahl, Tobias Schmidt; Waage, Anders; Standal, Therese (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    Interleukin-32 (IL-32) is a nonclassical cytokine expressed in cancers, inflammatory diseases, and infections. Its expression is regulated by two different oxygen sensing systems; HIF1α and cysteamine dioxygenase (ADO), ...
  • Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial 
    Sonja Zweegman, Zweegman; Claudia A M Stege, A; Haukås, Einar; Schjesvold, Fredrik H; Mark-David Levin, Levin; Waage, Anders; Rineke B L Leys, B; Saskia K Klein, K; Szatkowski, Damian Lukasz; Per Axelsson, Axelsson; Trung Hieu Do, Hieu; Dorota Knut-Bojanowska, Knut-Bojanowska; Ellen van der Spek, van; Asta Svirskaite, Svirskaite; Anja Klostergaard, Klostergaard; Morten Salomo, Salomo; Celine Blimark, Blimark; Paula F Ypma, F; Ulf-Henrik Mellqvist, Mellqvist; Pino J Poddighe, J; Marian Stevens-Kroef, Stevens-Kroef; Niels W C J van de Donk, W; Pieter Sonneveld, Sonneveld; Markus Hansson, Hansson; Bronno van der Holt, van; Niels Abildgaard, Abildgaard (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)
  • Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia – Follow-up of the RITP study 
    Tjønnfjord, Eirik; Holme, Pål Andre; Darne, Bernadette; Khelif, Abderrahim; Waage, Anders; Michel, Marc; Romdhan, Neila Ben; Ghanima, Waleed Khalid (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)
    RITP was a double‐blind randomized, 78‐week follow‐up trial in which 109 adults with immune thrombocytopenias (ITP) who failed to achieve adequate response to steroids, were randomized to receive rituximab or placebo. Here, ...
  • Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines 
    Giliberto, Mariaserena; Miranda Santana, Leonardo; Holien, Toril; Misund, Kristine; Nakken, Sigve; Vodak, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Coward, Eivind; Waage, Anders; Tasken, Kjetil; Skånland, Sigrid S (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Introduction Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet ...